Anika Therapeutics Inc. announced it will release its second quarter 2025 financial results on July 30, 2025, followed by a conference call to discuss the results and business highlights. The call will be accessible via phone and webcast, with materials available on the company's investor relations page.

Anika Therapeutics stockholders approved an amendment to the company’s 2017 Omnibus Incentive Plan, increasing reserved shares and expanding grant options. Directors Cheryl R. Blanchard, Joseph H. Capper, and Glenn R. Larsen were elected, with Deloitte & Touche LLP appointed as auditors. The company reported Q1 2025 financial results below expectations, including negative EPS and revenue shortfalls, while highlighting resilience in the commercial channel and future growth opportunities.

Anika Therapeutics granted non-statutory stock options covering 2,500 shares at $11.45 per share to a newly hired non-executive employee, with one-third vesting annually over three years and expiring on the tenth anniversary. The grant was made under the 2021 Inducement Plan, approved by the board of directors, as a material inducement for employment.

Anika Therapeutics Inc. granted non-statutory stock options to a newly hired non-executive employee under its 2021 Inducement Plan, with terms including vesting over three years and an expiration date ten years after the grant. The company, a global leader in osteoarthritis pain management and regenerative solutions, is headquartered outside Boston, Massachusetts.

The global Cartilage Repair market was valued at USD 1.3 billion in 2024 and is projected to reach USD 3.4 billion by 2033, growing at a 11.5% CAGR from 2025 to 2033. Key drivers include osteoarthritis prevalence, regenerative medicine advancements, and healthcare policy reforms. North America dominates the market, while Asia-Pacific is expected to grow fastest due to improving healthcare infrastructure. The report analyzes market segments, key players, and regional dynamics.